Top

Current Gastroenterology Reports

Published in:

01-12-2020 | Obesity | Endoscopy and Surgery (S Komanduri, Section Editor)

Endobariatrics and Metabolic Endoscopy: Can We Solve the Obesity Epidemic with Our Scope?

Authors: Jad Farha, Shahem Abbarh, Zadid Haq, Mohamad I. Itani, Andreas Oberbach, Vivek Kumbhari, Dilhana Badurdeen

Published in: Current Gastroenterology Reports | Issue 12/2020

Abstract

Purpose of Review

Obesity is a chronic relapsing disease that results in cardiovascular disease, diabetes mellitus, and non-alcoholic fatty liver disease. Currently, surgery represents the most effective treatment. However, the advent of minimally invasive endoscopic bariatric therapy (EBT) has shifted the treatment paradigm to less invasive, cost-effective procedures with minimal complications and recovery time that are preferred by patients. In this review, we will describe current and future EBTs, focusing on outcomes and safety.

Recent Findings

The endoscope has provided an incisionless portal into the gastrointestinal tract for placement of space-occupying devices and intraluminal procedures. EBTs are no longer solely manipulating anatomic alterations; instead, they aim to improve metabolic parameters such as glycated hemoglobin, low-density lipoprotein, cholesterol, and hepatic indices by targeting the mucosal layer of the gastrointestinal tract.

Summary

The endoscope has succeeded in facilitating clinically meaningful weight loss and improvement of metabolic parameters. Future, solutions to the obesity epidemic will likely entail genetic testing, evaluation of the microbiome, and delivery of personalized therapy, utilizing combination endoscopic modalities that change the anatomy and physiology of individual patients, with new targets such as the abnormal metabolic signal.

Mason EE, Ito C. Gastric bypass in obesity. 1967. Obes Res. 1996;4(3):316–9.PubMed

Alden JF. Gastric and jejunoileal bypass. A comparison in the treatment of morbid obesity. Arch Surg. 1977;112(7):799–806.PubMed

Griffen WO Jr, Young VL, Stevenson CC. A prospective comparison of gastric and jejunoileal bypass procedures for morbid obesity. Ann Surg. 1977;186(4):500–9.PubMedPubMedCentral

Fung M, Wharton S, Macpherson A, Kuk JL. Receptivity to bariatric surgery in qualified patients. J Obes. 2016;2016:5372190.PubMedPubMedCentral

Ginsberg GG, Chand B, Cote GA, Dallal RM, Edmundowicz SA, Nguyen NT, et al. A pathway to endoscopic bariatric therapies. Gastrointest Endosc. 2011;74(5):943–53.PubMed

Gómez V. Making a U-turn at the stomach. Gastrointest Endosc. 2019;90(5):781–3.PubMed

Abu Dayyeh BK, Acosta A, Camilleri M, Mundi MS, Rajan E, Topazian MD, et al. Endoscopic sleeve gastroplasty alters gastric physiology and induces loss of body weight in obese individuals. Clin Gastroenterol Hepatol. 2017;15(1):37–43.e1.PubMed

Lopez-Nava G, Sharaiha RZ, Vargas EJ, Bazerbachi F, Manoel GN, Bautista-Castano I, et al. Endoscopic sleeve gastroplasty for obesity: a multicenter study of 248 patients with 24 months follow-up. Obes Surg. 2017;27(10):2649–55.PubMed

Alqahtani A, Al-Darwish A, Mahmoud AE, Alqahtani YA, Elahmedi M. Short-term outcomes of endoscopic sleeve gastroplasty in 1000 consecutive patients. Gastrointest Endosc. 2019;89(6):1132–8.PubMed

10.

Barrichello S, Hourneaux de Moura DT, Hourneaux de Moura EG, Jirapinyo P, Hoff AC, Fittipaldi-Fernandez RJ, et al. Endoscopic sleeve gastroplasty in the management of overweight and obesity: an international multicenter study. Gastrointest Endosc. 2019;90(5):770–80.PubMed

11.

Sartoretto A, Sui Z, Hill C, Dunlap M, Rivera AR, Khashab MA, et al. Endoscopic sleeve gastroplasty (ESG) is a reproducible and effective endoscopic bariatric therapy suitable for widespread clinical adoption: a large. Int Multicenter Study Obes Surg. 2018;28(7):1812–21.

12.

James TW, Reddy S, Vulpis T, McGowan CE. Endoscopic sleeve gastroplasty is feasible, safe, and effective in a non-academic setting: short-term outcomes from a community gastroenterology practice. Obes Surg. 2020;30(4):1404–9.PubMed

13.

Graus Morales J, Crespo Perez L, Marques A, Marin Arribas B, Bravo Arribas R, Ramo E, et al. Modified endoscopic gastroplasty for the treatment of obesity. Surg Endosc. 2018;32(9):3936–42.PubMed

14.

Lopez-Nava G, Galvao MP, Bautista-Castano I, Fernandez-Corbelle JP, Trell M, Lopez N. Endoscopic sleeve gastroplasty for obesity treatment: two years of experience. Arq Bras Cir Dig. 2017;30(1):18–20.PubMedPubMedCentral

15.

Hedjoudje A, Dayyeh BA, Cheskin LJ, Adam A, Neto MG, Badurdeen D, et al. Efficacy and safety of endoscopic sleeve gastroplasty: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2019.

16.

Singh S, de Moura DTH, Khan A, Bilal M, Ryan MB, Thompson CC. Safety and efficacy of endoscopic sleeve gastroplasty worldwide for treatment of obesity: a systematic review and meta-analysis. Surg Obes Relat Dis. 2020;16(2):340–51.PubMed

17.

Itani MI, Farha J, Marrache MK, Fayad L, Badurdeen D, Kumbhari V. The effects of bariatric surgery and endoscopic bariatric therapies on GERD: an update. Curr Treat Options Gastroenterol. 2020;18:97–108.

18.

Runge TM, Yang J, Fayad L, Itani MI, Dunlap M, Koller K, et al. Correction to: anatomical configuration of the stomach post-endoscopic sleeve gastroplasty (ESG)-what are the sutures doing? Obes Surg. 2020;30(5):2061.PubMed

19.

Hajifathalian K, Ang B, Dawod QM, Shah SL, Dawod E, Mehta A, et al. 175 Long-term follow up and outcomes after endoscopic sleeve gastroplasty for treatment of obesity (5 year data). Gastrointest Endosc. 2019;89(6):AB58.

20.

Fayad L, Cheskin LJ, Adam A, Badurdeen DS, Hill C, Agnihotri A, et al. Endoscopic sleeve gastroplasty versus intragastric balloon insertion: efficacy, durability, and safety. Endoscopy. 2019;51(6):532–9.PubMed

21.

Cheskin LJ, Hill C, Adam A, Fayad L, Dunlap M, Badurdeen D, et al. Endoscopic sleeve gastroplasty versus high-intensity diet and lifestyle therapy: a case-matched study. Gastrointest Endosc. 2020;91(2):342–9.e1.PubMed

22.

Fayad L, Adam A, Schweitzer M, Cheskin LJ, Ajayi T, Dunlap M, et al. Endoscopic sleeve gastroplasty versus laparoscopic sleeve gastrectomy: a case-matched study. Gastrointest Endosc. 2019;89(4):782–8.PubMed

23.

Badurdeen DS, Kumbhari V. Endoscopic sleeve gastroplasty and its application to China. J Dig Dis. 2017;18(10):551–5.PubMed

24.

Sharaiha RZ, Kumta NA, Saumoy M, Desai AP, Sarkisian AM, Benevenuto A, et al. Endoscopic sleeve gastroplasty significantly reduces body mass index and metabolic complications in obese patients. Clin Gastroenterol Hepatol. 2017;15(4):504–10.PubMed

25.

López-Nava G, Bautista-Castaño I, Jimenez A, De Grado T, Fernandez-Corbelle JP. The Primary Obesity Surgery Endolumenal (POSE) procedure: one-year patient weight loss and safety outcomes. Surg Obes Relat Dis. 2015;11(4):861–5.PubMed

26.

Jirapinyo P, Thompson CC. Gastric plications for weight loss: distal primary obesity surgery endoluminal through a belt-and-suspenders approach. VideoGIE. 2018;3(10):296–300.PubMedPubMedCentral

27.

Jirapinyo P, Thompson CC. Endoscopic gastric body plication for the treatment of obesity: technical success and safety of a novel technique (with video). Gastrointest Endosc. 2020;91(6):1388–94.PubMed

28.

Lopez-Nava G, Asokkumar R, Turró Arau R, Neto MG, Dayyeh BA. Modified primary obesity surgery endoluminal (POSE-2) procedure for the treatment of obesity. VideoGIE. 2020;5(3):91–3.PubMedPubMedCentral

29.

Espinós J, Turró R, Mata A, Cruz M, Da Costa M, Villa V, et al. Early experience with the Incisionless Operating Platform™(IOP) for the treatment of obesity. Obes Surg. 2013;23(9):1375–83.PubMed

30.

Sullivan S, Swain JM, Woodman G, Antonetti M, De La Cruz-Muñoz N, Jonnalagadda SS, et al. Randomized sham-controlled trial evaluating efficacy and safety of endoscopic gastric plication for primary obesity: the ESSENTIAL trial. Obesity (Silver Spring). 2017;25(2):294–301.

31.

Lerner H, Whang J, Nipper R. Benefit-risk paradigm for clinical trial design of obesity devices: FDA proposal. Surg Endosc. 2013;27(3):702–7.PubMed

32.

Miller K, Turró R, Greve JW, Bakker CM, Buchwald JN, Espinós JC. MILEPOST multicenter randomized controlled trial: 12-month weight loss and satiety outcomes after pose (SM) vs. Med Ther Obes Surg. 2017;27(2):310–22.

33.

Espinós JC, Turró R, Moragas G, Bronstone A, Buchwald JN, Mearin F, et al. Gastrointestinal physiological changes and their relationship to weight loss following the POSE procedure. Obes Surg. 2016;26(5):1081–9.PubMed

34.

Kumar N, Sullivan S, Thompson CC. The role of endoscopic therapy in obesity management: intragastric balloons and aspiration therapy. Diabetes Metab Syndr Obes. 2017;10:311–6.PubMedPubMedCentral

35.

Barrichello S, Badurdeen D, Hedjoudje A, Neto MG, Yance R, Veinert A, et al. The effect of the intra-gastric balloon on gastric emptying and the DeMeester score. Obes Surg. 2020;30(1):38–45.PubMed

36.

ORBERA™ Intragastric Balloon System; directions for use. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf14/P140008c.pdf. Accessed 15 June 2020.

37.

Agnihotri A, Xie A, Bartalos C, Kushnir V, Sullivan S, Islam S, et al. Real-world safety and efficacy of fluid-filled dual intragastric balloon for weight loss. Clin Gastroenterol Hepatol. 2018;16(7):1081–8.e1.PubMed

38.

Apollo Endosurgery. News about ReShape ready. 2018. Available from: https://www.orbera.com/reshape/. Accessed 15 June 2020.

39.

Neto MG, Silva LB, Grecco E, de Quadros LG, Teixeira A, Souza T, et al. Brazilian intragastric balloon consensus statement (BIBC): practical guidelines based on experience of over 40,000 cases. Surg Obes Relat Dis. 2018;14(2):151–9.PubMed

40.

Ball W, Raza SS, Loy J, Riera M, Pattar J, Adjepong S, et al. Effectiveness of intra-gastric balloon as a bridge to definitive surgery in the super obese. Obes Surg. 2019;29(6):1932–6.PubMed

41.

U.S. Food and Drug Administration. ORBERA™ Intragastric Balloon System - P140008. Available from: https://wayback.archive-it.org/7993/20171114155604/https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm457416.htm. Accessed 15 June 2020.

42.

Dayyeh BKA, Eaton LL, Woodman G, Fusco M, Shayani V, Billy HT, et al. 444 a randomized, multi-center study to evaluate the safety and effectiveness of an intragastric balloon as an adjunct to a behavioral modification program, in comparison with a behavioral modification program alone in the weight management of obese subjects. Gastrointest Endosc. 2015;81(5):AB147.

43.

Abu Dayyeh BK, Kumar N, Edmundowicz SA, Jonnalagadda S, Larsen M, Sullivan S, et al. ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest Endosc. 2015;82(3):425–38.e5.PubMed

44.

Kotzampassi K, Grosomanidis V, Papakostas P, Penna S, Eleftheriadis E. 500 intragastric balloons: what happens 5 years thereafter? Obes Surg. 2012;22(6):896–903.PubMed

45.

Orbera PAS study, Food and Drug Administration. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma_pas.cfm?t_id=534908&c_id=3558. Accessed 15 June 2020.

46.

Dumonceau JM, Francois E, Hittelet A, Mehdi AI, Barea M, Deviere J. Single vs repeated treatment with the intragastric balloon: a 5-year weight loss study. Obes Surg. 2010;20(6):692–7.PubMed

47.

Genco A, Cipriano M, Bacci V, Maselli R, Paone E, Lorenzo M, et al. Intragastric balloon followed by diet vs intragastric balloon followed by another balloon: a prospective study on 100 patients. Obes Surg. 2010;20(11):1496–500.PubMed

48.

Mitura K, Garnysz K. Tolerance of intragastric balloon and patient’s satisfaction in obesity treatment. Wideochir Inne Tech Maloinwazyjne. 2015;10(3):445–9.PubMedPubMedCentral

49.

Barola S, Agnihotri A, Chang Chiu A, Kalloo AN, Kumbhari V. Spontaneous hyperinflation of an Intragastric balloon 5 months after insertion. Am J Gastroenterol. 2017;112(3):412.PubMed

50.

Fayad L, Simsek C, Khashab MA, Kalloo AN, Kumbhari V. Gastrointestinal: Intragastric balloon: gastric outlet obstruction or resting in the antrum? J Gastroenterol Hepatol. 2019;34(1):8.PubMed

51.

FDA; Update: potential risks with liquid-filled intragastric balloons - letter to health care providers. Available from: https://www.fda.gov/medical-devices/letters-health-care-providers/update-potential-risks-liquid-filled-intragastric-balloons-letter-health-care-providers-1. Accessed 15 June 2020.

52.

Bazerbachi F, Vargas EJ, Rizk M, Maselli DB, Mounajjed T, Venkatesh SK, et al. Intragastric balloon placement induces significant metabolic and histologic improvement in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2020;S1542-3565(20)30613–3. https://doi.org/10.1016/j.cgh.2020.04.068.

53.

U.S. Food and Drug Administration. Obalon Balloon System - P160001. Available from: https://wayback.archive-it.org/7993/20171114155511/https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm520741.htm. Accessed 15 June 2020.

54.

Sullivan S, Swain J, Woodman G, Edmundowicz S, Hassanein T, Shayani V, et al. Randomized sham-controlled trial of the 6-month swallowable gas-filled intragastric balloon system for weight loss. Surg Obes Relat Dis. 2018;14(12):1876–89.PubMed

55.

Bazerbachi F, Haffar S, Sawas T, Vargas EJ, Kaur RJ, Wang Z, et al. Fluid-filled versus gas-filled intragastric balloons as obesity interventions: a network meta-analysis of randomized trials. Obes Surg. 2018;28(9):2617–25.PubMed

56.

Brooks J, Srivastava ED, Mathus-Vliegen EM. One-year adjustable intragastric balloons: results in 73 consecutive patients in the U.K. Obes Surg. 2014;24(5):813–9.PubMed

57.

Russo T, Aprea G, Formisano C, Ruggiero S, Quarto G, Serra R, et al. BioEnterics Intragastric Balloon (BIB) versus Spatz adjustable balloon system (ABS): our experience in the elderly. Int J Surg. 2017;38:138–40.PubMed

58.

Machytka E, Divi VP, Saenger F, Sorio R, Brooks J. Mo1296a adjustable balloons for weight loss: a higher yield of responders compared with non-adjustable balloons. Gastrointest Endosc. 2017;85(5):AB495.

59.

Usuy E, Brooks J. Response rates with the Spatz3 adjustable balloon. Obes Surg. 2018;28(5):1271–6.PubMed

60.

Administration USFaD. AspireAssist obesity device. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-aspireassist-obesity-device. Accessed 15 June 2020.

61.

Thompson CC, Dayyeh BKA, Kushner R, Sullivan S, Schorr AB, Amaro A, et al. Percutaneous gastrostomy device for the treatment of class II and class III obesity: results of a randomized controlled trial. Am J Gastroenterol. 2017;112(3):447–57.PubMed

62.

Thompson CC, Abu Dayyeh BK, Kushnir V, Kushner RF, Jirapinyo P, Schorr AB, et al. Aspiration therapy for the treatment of obesity: 4-year results of a multicenter randomized controlled trial. Surg Obes Relat Dis. 2019;15(8):1348–54.PubMed

63.

Jirapinyo P, de Moura DTH, Horton LC, Thompson CC. Effect of aspiration therapy on obesity-related comorbidities: systematic review and meta-analysis. Clin Endosc. 2020. https://doi.org/10.5946/ce.2019.181.

64.

Kumbhari V, Okolo PI III. Editorial: aspiration therapy for weight loss: is the squeeze worth the juice? Am J Gastroenterol. 2017;112(3):458–589.PubMed

65.

Gjeorgjievski M, Reddy N, Stecevic V, Cappell MS. Abdominal abscess related to endoscopically placed AspireAssist® device. ACG Case Rep J. 2018;5:e12.PubMedPubMedCentral

66.

U.S. Food and Drug Administration. TransPyloric Shuttle - P180024. Available from: https://www.fda.gov/medical-devices/recently-approved-devices/transpyloric-shuttletranspyloric-shuttle-delivery-device-p180024. Accessed 15 June 2020.

67.

Marinos G, Eliades C, Muthusam VR, Greenway F. Weight loss and improved quality of life with a nonsurgical endoscopic treatment for obesity: clinical results from a 3- and 6-month study. Surg Obes Relat Dis. 2014;10(5):929–34.PubMed

68.

Rothstein R, Woodman G, Swain J, Cruz NDL, Kushnir V, Pryor A, et al. Transpyloric shuttle treatment improves cardiometabolic risk factors and quality of life in patients with obesity: results from a randomized, double-blind, Sham-Controlled Trial. Gastroenterology. 2019;156(6):S-237.

69.

Park J, Bakheet N, Na H, Jeon J, Yoon S, Kim K, et al. A novel full sense device to treat obesity in a porcine model: preliminary results. Obes Surg. 2019;29(5):1521–7.PubMed

70.

Luo Y, Zhang X, Tsauo J, Jung H, Song H, Zhao H, et al. Intragastric satiety-inducing device reduces food intake and suppresses body weight gain in a rodent model. Surg Endosc. 2020;24:1–6.

71.

Sjöström L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351(26):2683–93.PubMed

72.

Thaler JP, Cummings DE. Minireview: hormonal and metabolic mechanisms of diabetes remission after gastrointestinal surgery. Endocrinology. 2009;150(6):2518–25.PubMed

73.

Breen DM, Rasmussen BA, Kokorovic A, Wang R, Cheung GW, Lam TK. Jejunal nutrient sensing is required for duodenal-jejunal bypass surgery to rapidly lower glucose concentrations in uncontrolled diabetes. Nat Med. 2012;18(6):950–5.PubMed

74.

Rodriguez L, Reyes E, Fagalde P, Oltra MS, Saba J, Aylwin CG, et al. Pilot clinical study of an endoscopic, removable duodenal-jejunal bypass liner for the treatment of type 2 diabetes. Diabetes Technol Ther. 2009;11(11):725–32.PubMed

75.

Koehestanie P, de Jonge C, Berends FJ, Janssen IM, Bouvy ND, Greve JW. The effect of the endoscopic duodenal-jejunal bypass liner on obesity and type 2 diabetes mellitus, a multicenter randomized controlled trial. Ann Surg. 2014;260(6):984–92.PubMed

76.

de Moura EG, Martins BC, Lopes GS, Orso IR, de Oliveira SL, Galvão Neto MP, et al. Metabolic improvements in obese type 2 diabetes subjects implanted for 1 year with an endoscopically deployed duodenal-jejunal bypass liner. Diabetes Technol Ther. 2012;14(2):183–9.PubMed

77.

Rohde U, Hedbäck N, Gluud LL, Vilsbøll T, Knop FK. Effect of the EndoBarrier gastrointestinal liner on obesity and type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2016;18(3):300–5.PubMed

78.

Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese (ENDO). Available from: https://clinicaltrials.gov/ct2/show/NCT01728116. Accessed 15 June 2020.

79.

Betzel B, Drenth JP, Siersema PD. Adverse events of the duodenal-jejunal bypass liner: a systematic review. Obes Surg. 2018;28(11):3669–77.PubMed

80.

Sandler BJ, Rumbaut R, Swain CP, Torres G, Morales L, Gonzales L, et al. One-year human experience with a novel endoluminal, endoscopic gastric bypass sleeve for morbid obesity. Surg Endosc. 2015;29(11):3298–303.PubMed

81.

ValenTx I. The ValenTx endo bypass system in obese subjects. 2016. Available from: In: ClinicalTrials.gov. 2016. https://clinicaltrials.gov/ct2/show/NCT02954003. Accessed 15 June 2020.

82.

Badurdeen DS, Fayad L, Kalloo AN, Kumbhari V. The forgotten fundus-response to - obesity treatment with botulinum toxin-a is not effective: a systematic review and meta-analysis. Obes Surg. 2018;28(1):262–3.PubMed

83.

Bustamante F, Brunaldi VO, Bernardo WM, de Moura DTH, de Moura ETH, Galvão M, et al. Obesity treatment with botulinum toxin-a is not effective: a systematic review and meta-analysis. Obes Surg. 2017;27(10):2716–23.PubMed

84.

Foschi D, Corsi F, Lazzaroni M, Sangaletti O, Riva P, La Tartara G, et al. Treatment of morbid obesity by intraparietogastric administration of botulinum toxin: a randomized, double-blind, controlled study. Int J Obes. 2007;31(4):707–12.

85.

Technology NUoSa. Treatment of morbid obesity by intragastric injections of botulinum toxin A. A randomized, double-blind, placebo controlled, phase II-trial. Available from: https://clinicaltrials.gov/ct2/show/NCT02035397. Accessed 15 June 2020.

86.

Cherrington AD, Rajagopalan H, Maggs D, Devière J. Hydrothermal duodenal mucosal resurfacing: role in the treatment of metabolic disease. Gastrointest Endosc Clin. 2017;27(2):299–311.

87.

Rajagopalan H, Cherrington AD, Thompson CC, Kaplan LM, Rubino F, Mingrone G, et al. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes: 6-month interim analysis from the first-in-human proof-of-concept study. Diabetes Care. 2016;39(12):2254–61.PubMed

88.

van Baar AC, Holleman F, Crenier L, Haidry R, Magee C, Hopkins D, et al. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus: one year results from the first international, open-label, prospective, multicentre study. Gut. 2020;69(2):295–303.PubMed

89.

van Baar AC, Beuers U, Wong K, Haidry R, Costamagna G, Hafedi A, et al. Endoscopic duodenal mucosal resurfacing improves glycaemic and hepatic indices in type 2 diabetes: 6-month multicentre results. JHEP Rep. 2019;1(6):429–37.PubMedPubMedCentral

90.

Machytka E, Bužga M, Zonca P, Lautz DB, Ryou M, Simonson DC, et al. Partial jejunal diversion using an incisionless magnetic anastomosis system: 1-year interim results in patients with obesity and diabetes. Gastrointest Endosc. 2017;86(5):904–12.PubMed

91.

Ryou M, Agoston AT, Thompson CC. Endoscopic intestinal bypass creation by using self-assembling magnets in a porcine model. Gastrointest Endosc. 2016;83(4):821–5.PubMed

92.

Kluge F, Seidler E. First use of Osophago and gastroscopy: letters from Adolf Kussmaul and his staff. Med J. 1986;21(3–4):288–307.

93.

Hirschowitz BI, Curtiss LE, Peters CW, Pollard HM. Demonstration of a new gastroscope, the fiberscope. Gastroenterology. 1958;35(1):50; discussion 1-3–3.PubMed

94.

Sivak MV Jr, Fleischer DE. Colonoscopy with a videoendoscope: preliminary experience. Gastrointest Endosc. 1984;30(1):1–5.PubMed

95.

Fayad L, Oberbach A, Schweitzer M, Askin F, Voltaggio L, Larman T, et al. Gastric mucosal devitalization (GMD): translation to a novel endoscopic metabolic therapy. Endosc Int Open. 2019;7(12):E1640–e5.PubMedPubMedCentral

96.

Kumbhari V, Lehmann S, Schlichting N, Heinrich M, Kullnick Y, Retschlag U, et al. Gastric mucosal devitalization is safe and effective in reducing body weight and visceral adiposity in a porcine model. Gastrointest Endosc. 2018;88(1):175–84.e1.PubMed

97.

Oberbach A, Schlichting N, Heinrich M, Kullnick Y, Retschlag U, Lehmann S, et al. Gastric mucosal devitalization reduces adiposity and improves lipid and glucose metabolism in obese rats. Gastrointest Endosc. 2018;87(1):288–99.e6.PubMed

98.

Kelly CR, Khoruts A, Staley C, Sadowsky MJ, Abd M, Alani M, et al. Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection: a randomized trial. Ann Intern Med. 2016;165(9):609–16.PubMedPubMedCentral

99.

Youngster I, Sauk J, Pindar C, Wilson RG, Kaplan JL, Smith MB, et al. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin Infect Dis. 2014;58(11):1515–22.PubMedPubMedCentral

100.

Van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368(5):407–15.PubMed

101.

Choi HH, Cho Y-S. Fecal microbiota transplantation: current applications, effectiveness, and future perspectives. Clin Endosc. 2016;49(3):257–65.PubMedPubMedCentral

102.

Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JF, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012;143(4):913–6. e7.PubMed

103.

Yu EW. Fecal microbiota transplant for obesity and metabolism. https://www.clinicaltrials.gov/ct2/show/NCT02530385. Accessed 15 June 2020.

104.

Thompson CC, Fecal microbiota transplantation for the treatment of obesity (FMT obesity). 2017. Available from: https://clinicaltrials.gov/ct2/show/NCT02741518. Accessed 15 June 2020.

105.

Center T-ASM. Fecal microbiota transplantation for diabetes mellitus type II in obese patients 2016. Available from: https://clinicaltrials.gov/ct2/show/NCT02346669. Accessed 15 June 2020.

106.

Silverman M. Transplantation of microbes for treatment of metabolic syndrome and NAFLD (FMT). NihGov, vol NCT02496390. 2016.

Title: Endobariatrics and Metabolic Endoscopy: Can We Solve the Obesity Epidemic with Our Scope?
Authors: Jad Farha
Shahem Abbarh
Zadid Haq
Mohamad I. Itani
Andreas Oberbach
Vivek Kumbhari
Dilhana Badurdeen
Publication date: 01-12-2020
Publisher: Springer US
Keywords: Obesity
Endoscopy
Obesity
Published in: Current Gastroenterology Reports / Issue 12/2020
Print ISSN: 1522-8037
Electronic ISSN: 1534-312X
DOI: https://doi.org/10.1007/s11894-020-00798-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 12/2020

Causes and Management of Non-cirrhotic Portal Hypertension​

Inflammatory Bowel Disease Environmental Risk Factors: Diet and Gut Microbiota

Determining the Indeterminate Biliary Stricture: Cholangioscopy and Beyond

Advances in Biliary Access

Endoscopic Eradication Therapy for Barrett’s Neoplasia: Where Do We Stand a Decade Later?

Emerging Therapies to Prevent Post-ERCP Pancreatitis

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage

Causes and Management of Non-cirrhotic Portal Hypertension